MX2022007471A - Metodos de tratamiento de la nefropatia por iga con atrasentan. - Google Patents
Metodos de tratamiento de la nefropatia por iga con atrasentan.Info
- Publication number
- MX2022007471A MX2022007471A MX2022007471A MX2022007471A MX2022007471A MX 2022007471 A MX2022007471 A MX 2022007471A MX 2022007471 A MX2022007471 A MX 2022007471A MX 2022007471 A MX2022007471 A MX 2022007471A MX 2022007471 A MX2022007471 A MX 2022007471A
- Authority
- MX
- Mexico
- Prior art keywords
- decreasing
- nephropathy
- subject
- atrasentan
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949115P | 2019-12-17 | 2019-12-17 | |
| US202063005003P | 2020-04-03 | 2020-04-03 | |
| US202063072699P | 2020-08-31 | 2020-08-31 | |
| US202063084739P | 2020-09-29 | 2020-09-29 | |
| US202063125205P | 2020-12-14 | 2020-12-14 | |
| PCT/US2020/065311 WO2021126977A1 (en) | 2019-12-17 | 2020-12-16 | Methods of treating iga nephropathy with atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007471A true MX2022007471A (es) | 2022-08-17 |
Family
ID=76478538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007471A MX2022007471A (es) | 2019-12-17 | 2020-12-16 | Metodos de tratamiento de la nefropatia por iga con atrasentan. |
Country Status (13)
| Country | Link |
|---|---|
| US (11) | US20210353593A1 (enExample) |
| EP (1) | EP4076652B1 (enExample) |
| JP (2) | JP7624995B2 (enExample) |
| KR (1) | KR20230015874A (enExample) |
| CN (3) | CN116327758A (enExample) |
| AU (1) | AU2020404984A1 (enExample) |
| BR (1) | BR112022012075A2 (enExample) |
| CA (1) | CA3161516A1 (enExample) |
| IL (1) | IL293921A (enExample) |
| MX (1) | MX2022007471A (enExample) |
| PH (1) | PH12022551456A1 (enExample) |
| TW (1) | TWI875895B (enExample) |
| WO (1) | WO2021126977A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293921A (en) | 2019-12-17 | 2022-08-01 | Chinook Therapeutics Inc | Methods for treating iga kidney disease with atresantan |
| CN114910647A (zh) * | 2022-05-07 | 2022-08-16 | 浙江大学 | 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用 |
| WO2023220930A1 (en) * | 2022-05-17 | 2023-11-23 | Increvet, Inc. | Veterinary pharmaceutical formulations cross-references to related applications |
| CA3252232A1 (en) * | 2022-05-19 | 2023-11-23 | Chinook Therapeutics, Inc. | METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| IL320469A (en) * | 2022-10-28 | 2025-06-01 | Chinook Therapeutics Inc | Treatment of IGA nephropathy with an endothelin receptor antagonist and an APRIL-binding antibody |
| AU2023378052A1 (en) | 2022-11-07 | 2025-05-29 | Chinook Therapeutics, Inc. | Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5236940A (en) | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US20020062121A1 (en) | 1995-05-16 | 2002-05-23 | Karl Tryggvason | Perfusion apparatus and methods for pharmaceutical delivery |
| PT885215E (pt) | 1996-02-13 | 2006-08-31 | Abbott Lab | Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina |
| US20040191774A1 (en) | 2001-09-11 | 2004-09-30 | Moskowitz David W | Endothelin-1 promoter polymorphism |
| MXPA04009234A (es) | 2002-03-22 | 2005-01-25 | Kissei Pharmaceutical | Agente preventivo o terapeutico para enfermedades renales. |
| AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US20030229906A1 (en) | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| DE602005022871D1 (de) | 2004-06-07 | 2010-09-23 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
| JP2008513481A (ja) | 2004-09-17 | 2008-05-01 | アボット・ラボラトリーズ | アトラセンタン塩酸塩の結晶形２ |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| WO2007109244A2 (en) | 2006-03-21 | 2007-09-27 | Morehouse School Of Medicine | Novel nanoparticles for delivery of active agents |
| MX2008012276A (es) * | 2006-03-27 | 2008-10-08 | Genentech Inc | Metodos para el tratamiento de alteraciones del riñon. |
| SG174050A1 (en) | 2006-04-13 | 2011-09-29 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| CA2667364A1 (en) | 2007-01-16 | 2008-07-24 | Musc Foundation For Research Development | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| CN101801936B (zh) | 2007-07-31 | 2012-10-03 | 吉利德科罗拉多公司 | 安立生坦的代谢物和衍生物 |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| US20120083421A1 (en) | 2008-10-16 | 2012-04-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) |
| EP2413930A4 (en) | 2009-03-31 | 2012-09-26 | Ligand Pharm Inc | ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY |
| WO2011070049A1 (en) | 2009-12-09 | 2011-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| WO2012014663A1 (ja) | 2010-07-28 | 2012-02-02 | 日本電気硝子株式会社 | 蛍光体封入用毛細管の製造方法、蛍光体封入用毛細管、波長変換部材及び波長変換部材の製造方法 |
| HK1220209A1 (zh) * | 2013-03-08 | 2017-04-28 | Abbvie Inc. | 治疗急性肾损伤的方法 |
| AU2014259961A1 (en) | 2013-04-30 | 2015-11-05 | Abbvie, Inc. | Methods for improving lipid profiles using atrasentan |
| SG11201600107RA (en) | 2013-07-08 | 2016-02-26 | Abbvie Inc | Stabilized pharmaceutical dosage forms comprising atrasentan |
| US8962675B1 (en) * | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| WO2016073846A1 (en) * | 2014-11-07 | 2016-05-12 | Abbvie Inc. | Methods of treating ckd using predictors of fluid retention |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20170014386A1 (en) | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| MA43260A (fr) * | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| UA127339C2 (uk) | 2016-01-05 | 2023-07-26 | Юніверсіті Оф Лестер | СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN) |
| CN114788823A (zh) * | 2016-10-13 | 2022-07-26 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| CN110177549A (zh) | 2016-11-23 | 2019-08-27 | 坎莫森特里克斯公司 | 治疗局灶性节段性肾小球硬化的方法 |
| SG11202002975YA (en) | 2017-10-11 | 2020-04-29 | Chemocentryx Inc | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
| MA51203A (fr) | 2017-11-30 | 2020-10-07 | Idorsia Pharmaceuticals Ltd | Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline |
| US20220304979A1 (en) | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| IL293921A (en) * | 2019-12-17 | 2022-08-01 | Chinook Therapeutics Inc | Methods for treating iga kidney disease with atresantan |
| JP2023521169A (ja) | 2020-04-10 | 2023-05-23 | チヌーク セラピューティクス，インコーポレイテッド | 糖尿病性腎疾患の処置方法 |
| US20220243994A1 (en) | 2021-02-04 | 2022-08-04 | Northrop Grumman Systems Corporation | Metal woodpile capillary wick |
-
2020
- 2020-12-16 IL IL293921A patent/IL293921A/en unknown
- 2020-12-16 BR BR112022012075A patent/BR112022012075A2/pt unknown
- 2020-12-16 CN CN202310043260.6A patent/CN116327758A/zh active Pending
- 2020-12-16 TW TW109144568A patent/TWI875895B/zh active
- 2020-12-16 WO PCT/US2020/065311 patent/WO2021126977A1/en not_active Ceased
- 2020-12-16 MX MX2022007471A patent/MX2022007471A/es unknown
- 2020-12-16 KR KR1020227024511A patent/KR20230015874A/ko active Pending
- 2020-12-16 AU AU2020404984A patent/AU2020404984A1/en active Pending
- 2020-12-16 EP EP20903533.6A patent/EP4076652B1/en active Active
- 2020-12-16 CN CN202310043259.3A patent/CN116173014A/zh active Pending
- 2020-12-16 PH PH1/2022/551456A patent/PH12022551456A1/en unknown
- 2020-12-16 CA CA3161516A patent/CA3161516A1/en active Pending
- 2020-12-16 JP JP2022537007A patent/JP7624995B2/ja active Active
- 2020-12-16 CN CN202080007568.XA patent/CN113272013A/zh active Pending
-
2021
- 2021-06-30 US US17/363,604 patent/US20210353593A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/826,753 patent/US20220304978A1/en not_active Abandoned
- 2022-05-27 US US17/826,843 patent/US11491137B2/en active Active
- 2022-05-27 US US17/826,832 patent/US20220288026A1/en not_active Abandoned
- 2022-08-16 US US17/888,766 patent/US20230129646A1/en active Pending
-
2023
- 2023-07-18 US US18/223,355 patent/US12121509B2/en active Active
- 2023-07-18 US US18/223,340 patent/US11998526B2/en active Active
- 2023-07-18 US US18/223,290 patent/US20230355579A1/en not_active Abandoned
- 2023-11-29 US US18/523,609 patent/US20240108599A1/en active Pending
-
2024
- 2024-09-13 US US18/884,802 patent/US20250281454A1/en active Pending
- 2024-12-12 JP JP2024218275A patent/JP2025060686A/ja active Pending
- 2024-12-20 US US18/990,351 patent/US12370174B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551456A1 (en) | Methods of treating iga nephropathy with atrasentan | |
| MX2020010604A (es) | Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1). | |
| PH12022552702A1 (en) | Methods of treating diabetic kidney disease | |
| CO2022007953A2 (es) | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr | |
| MX2019008197A (es) | Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos. | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| ZA202203775B (en) | Substituted cyanopyrrolidines with activity as usp30 inhibitors | |
| CL2020001066A1 (es) | Compuestos y métodos para la reducción de la expresión de snca. | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX385898B (es) | Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa. | |
| WO2022218941A3 (en) | Compositions and methods for inhibiting ketohexokinase (khk) | |
| WO2018052891A3 (en) | MODULATION OF PCSK9 AND LDLR BY INHIBITION OF DRP1 | |
| WO2021038296A3 (en) | Modified tff2 polypeptides | |
| MX2025002106A (es) | Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica | |
| TW202545517A (zh) | 用阿曲生坦(ATRASENTAN)治療IgA腎病的方法 | |
| WO2020068950A8 (en) | Hdac1,2 inhibitors | |
| HK1250345A1 (zh) | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| EP4056638A4 (en) | COMPOSITION OF CELLULOSE, TABLET AND ORODISPERSIBLE TABLET | |
| CR20220588A (es) | Formulaciones farmacéuticas de acetato de abiraterona y niraparib | |
| MX2024013985A (es) | Metodos de tratamiento de la glomeruloesclerosis focal y segmentaria con atrasentan | |
| AU2018288712A1 (en) | Methods for treating merkel cell carcinoma (MCC) using NK-92 cells | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| ZA202201070B (en) | Focal treatment of prostate cancer |